Aromatase inhibitors for breast cancer: pharmacoeconomic considerations

Author： Higa Gerald M  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.2, Iss.6, 2001-06, pp. : 987-995

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Aromatase Inhibitors in Breast Cancer: A Review of Cost Considerations and Cost Effectiveness

By Karnon Jonathan  

PharmacoEconomics, Vol. 24, Iss. 3, 2006-01 ,pp. : 215-232

Adis International

Access to resources Recommend Favorite

Aromatase inhibitors and breast cancer prevention

By Litton Jennifer Keating   Arun Banu K   Brown Powel H   Hortobagyi Gabriel N  

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 3, 2012-02 ,pp. : 325-331

Informa Healthcare

Access to resources Recommend Favorite

Aromatase Inhibitors and Inactivators for Breast Cancer Therapy

By Lønning P.E.  

Drugs & Aging, Vol. 19, Iss. 4, 2002-04 ,pp. : 277-298

Adis International

Access to resources Recommend Favorite

Aromatase Inhibitors in the Treatment of Postmenopausal Breast Cancer

By Bajetta E.  

Drugs & Aging, Vol. 15, Iss. 4, 1999-10 ,pp. : 271-283

Adis International

Access to resources Recommend Favorite

Exemestane and aromatase inhibitors in the management of advanced breast cancer

By Dixon J Michael  

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 2, 2004-02 ,pp. : 307-316

Informa Healthcare

Access to resources Recommend Favorite